NVO Novo Nordisk

    By Dominic Chopping 
 

Danish pharmaceutical company Novo Nordisk AS said Friday that it has filed for European Union regulatory approval of its semaglutide weight-loss drug.

The company has submitted a Marketing Authorisation Application to the European Medicines Agency for semaglutide as a treatment for obese or overweight adults in conjunction with a reduced-calorie diet and increased physical activity.

Novo Nordisk earlier this month submitted a new drug application to the U.S. Food and Drug Administration for the drug.

"It is a milestone for Novo Nordisk but more importantly it represents a new treatment option with the potential to transform the medical management for people living with obesity in Europe," Novo Nordisk Chief Scientific Officer Mads Krogsgaard Thomsen said.

Semaglutide is a glucagon-like peptide-1 drug, or GLP-1, that helps enhance the production of insulin and regulate appetite.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

December 18, 2020 04:51 ET (09:51 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.